BeOne Medicines AG has entered into a new senior secured financing agreement with a group of financial institutions, including The Hongkong and Shanghai Banking Corporation Limited $(HSBC)$ as global coordinator. The Facilities Agreement, signed on November 13, 2025, provides BeOne Medicines with a U.S. dollar-denominated revolving loan facility of $140 million and a Renminbi-denominated term loan facility equivalent to approximately $300 million. The agreement includes financial covenants such as maintaining a minimum cash interest coverage ratio, net leverage ratio, and minimum consolidated shareholders' equity, among others. The initial drawdown is subject to customary regulatory approvals, and the agreement features an uncommitted accordion option that could increase total financing up to $700 million, although the company does not expect to exercise this option in the near term.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001651308-25-000148), on November 19, 2025, and is solely responsible for the information contained therein.
Comments